Isentress is the first medicine approved in a new class of antiretroviral drugs called integrase inhibitors. Isentress works by inhibiting the insertion of HIV DNA into human DNA by the integrase enzyme. Inhibiting integrase from performing this essential function limits the ability of the virus to replicate and infect new cells. There are drugs in use that inhibit two other enzymes critical to the HIV replication process - protease and reverse transcriptase - but Isentress is the only drug approved that inhibits the integrase enzyme.

Highest Dev Status	Approval
Therapeutic Area	Anti-Infective
Potential Indications	Please Login
Identified Action Mechanisms	2
Drug Website	http://www.isentress.com
Literature	NCBI